Copper and Zinc Ions Differentially Block Asialoglycoprotein Receptor-mediated Endocytosis in Isolated Rat Hepatocytes*

Douglas D. McAbeeDagger and Xin Jiang

From the Department of Chemistry and Biochemistry, California State University, Long Beach, California 90840

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Asialoglycoprotein receptors on hepatocytes lose endocytic and ligand binding activity when hepatocytes are exposed to iron ions. Here, we report the effects of zinc and copper ions on the endocytic and ligand binding activity of asialoglycoprotein receptors on isolated rat hepatocytes. Treatment of cells at 37 °C for 2 h with ZnCl2 (0-220 µM) or CuCl2 (0-225 µM) reversibly blocked sustained endocytosis of 125I-asialoorosomucoid by up to 93% (t1/2 = 62 min) and 99% (t1/2 = 54 min), respectively. Cells remained viable during such treatments. Zinc- and copper-treated cells lost ~50% of their surface asialoglycoprotein receptor ligand binding activity; zinc-treated cells accumulated inactive asialoglycoprotein receptors intracellularly, whereas copper-treated cells accumulated inactive receptors on their surfaces. Cells treated at 4 °C with metal did not lose surface asialoglycoprotein receptor activity. Exposure of cells to copper ions, but not to zinc ions, blocked internalization of prebound 125I-asialoorosomucoid, but degradation of internalized ligand and pinocytosis of the fluid-phase marker Lucifer Yellow were not blocked by metal treatment. Zinc ions reduced diferric transferrin binding and endocytosis on hepatocytes by ~33%; copper ions had no inhibitory effects. These findings are the first demonstration of a specific inhibition of receptor-mediated endocytosis by non-iron transition metals.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells require transition metals for a variety of crucial cellular processes, but unregulated accumulation of these metals, such as iron and copper ions, promotes damage to membrane lipids, proteins, and nucleic acids (1, 2). As a result, eukaryotic cells acquire nutrient metal ions by highly regulated mechanisms that also guard against overaccumulation of these metals, sequester metal ions when they are present in overabundance, and ameliorate the toxic effects of metals on cellular macromolecules (for reviews, see Refs. 3-5).

We have been studying the hepatic metabolism of the iron-binding protein lactoferrin and have found that rat hepatocytes take up lactoferrin via the rat hepatic lectin (RHL)1 1 subunit of the ASGP receptor. Unlike other characterized ligands for the ASGP receptor, lactoferrin binds at or near RHL1's carbohydrate recognition domain, yet in a carbohydrate-independent manner (6, 7). We have also found that the iron status of hepatocytes alters the manner in which hepatocytes bind and internalize lactoferrin. Iron loading of hepatocytes by incubation of cells with ferric ammonium citrate increases lactoferrin binding and endocytosis. This iron ion-dependent increase in lactoferrin accumulation, however, is accomplished by non-RHL1 binding sites that are reversibly expressed on cells in an iron-dependent manner reminiscent of iron-dependent regulation of ferritin (8, 9). In contrast, the endocytic activity of the ASGP receptor is dramatically inhibited by hepatocyte iron loading (8, 9). In addition, iron-replete hepatocytes accumulate up to half of their ASGP receptors in an inactive form, and these various effects correspond to the appearance of cystinyl-linked ASGP receptor RHL1 subunits (9). These findings represent a heretofore-unrecognized relationship between the ASGP receptor system and the iron status of hepatocytes.

Iron belongs to the borderline class of transition metals, which also includes Mn2+, Co2+, Ni2+, Cu2+, and Zn2+ (10). In general, borderline transition metals interact readily with organic ligands and are required by cells in trace amounts to carry out structural, catalytic, or redox activities. Because iron ion treatment of hepatocytes promoted formation of disulfide-bonded oligomers of RHL1 (9), we speculated that the iron-dependent inhibition of ASGP receptor function was related to the redox properties of iron ions. To address this matter, we initiated a study to examine the effects of other borderline transition metals (Mn2+, Cu2+, and Zn2+) with various redox capacities on ASGP receptor endocytic activity. Like iron ions, both manganese and copper ions can mediate intracellular redox reactions whereas zinc ions are not redox active. Here, we report that copper and zinc ions, but not manganese ions, dramatically block ASGP receptor-mediated endocytosis and receptor ligand binding activity. Moreover, zinc, but not copper, partially blocked internalization of transferrin by hepatocytes, but neither metal blocked intracellular processing of internalized ligand nor pinocytosis. Our findings are the first demonstration of a specific inhibition of receptor-mediated endocytosis by non-iron transition metals.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Human orosomucoid, human holotransferrin, neuraminidase (Clostridium perfringens), Lucifer Yellow (dipotassium salt), and BSA (fraction V) were purchased from Sigma. IODOGEN, IgG purification kit, and BCA protein assay reagent were obtained from Pierce). Collagenase (type D) was from Roche Molecular Biochemicals. Digitonin was obtained from Eastman Kodak. Na125I (17 Ci/mg of iodine) was from NEN Life Science Products. All other chemicals were reagent grade and obtained from Fisher Biochemicals (Itasca, IL or Tustin, CA) or Sigma. BME was obtained from Sigma and supplemented with 2.4 g/liter HEPES, pH 7.4, and 0.22 g/liter NaHCO3. BME-BSA is BME containing 0.1% (w/v) BSA. HBS contains 150 mM NaCl, 3 mM KCl, and 10 mM HEPES, pH 7.4. Buffer A contained HBS supplemented with 5 mM CaCl2 and 5 mM MgCl2. Buffer B contains HBS supplemented with 5 mM EGTA.

Hepatocyte Preparation-- Male Sprague-Dawley rats (100-350 g, Harlan Sprague, San Diego, CA) were fed standard laboratory chow and water ad libitum. The copper and zinc content of the chow (Purina Rodent Laboratory Chow, formula 5001) were 13 and 70 ppm, respectively, as assayed by the manufacturer. Hepatocytes were prepared by a modification of a collagenase perfusion procedure (11) as described previously (12). Cells were kept at approximately 30 °C during the filtration and differential centrifugation steps. Final cell pellets suspended in ice-cold BME-BSA were >= 85% viable and single cells. Before experiments, cell suspensions (2-4 × 106 cells/ml in BME-BSA, 10% of the flask volume) were incubated at 37 °C for 60 min to allow recovery from the isolation procedure. Cell viability was determined microscopically by trypan blue exclusion. For some experiments, isolated hepatocytes were plated on unmodified tissue culture plates at a density of ~1000 cells/mm2 in William's E medium supplemented with 5% (v/v) fetal bovine serum, 10 mM HEPES, 2 mM L-glutamine, 0.48 µg/ml insulin, 0.5 µM dexamethasone, 2.5 µg/ml amphotericin B, and 50 µg/ml gentamycin and incubated at 37 °C in 5% CO2 overnight prior to use.

Transferrin and ASOR Preparation-- Human holotransferrin and human orosomucoid (alpha 1-acid glycoprotein) were obtained commercially. Human orosomucoid was desialylated with neuraminidase as described previously (13), and removal of terminal N-acetylneuraminyl groups was confirmed by lectin blotting of neuraminidase-treated orosomucoid with Sambucus nigra agglutinin-digoxigenin conjugate (DIG glycan differentiation kit, Roche Molecular Biochemicals) as reported elsewhere (7). 125I-Transferrin and 125I-ASOR, prepared by the IODOGEN method (14), had specific activities of 90-130 dpm/fmol. Homogeneity and structural integrity of 125I-transferrin and 125I-ASOR were confirmed by denaturing electrophoresis followed by autoradiography.

125I-ASOR Binding, Endocytosis and Degradation Assays-- For 125I-ASOR binding assays, 2-4 × 106 cells/ml were routinely incubated with 125I-ASOR (1-2 µg/ml) at 4 °C for 60 min in either BME-BSA or Buffer A. Cells incubated with 125I-ASOR were washed free of unbound ligand by centrifugation in excess Buffer A (two 5-min washes, 4 °C). Washed cells were resuspended in 0.5-1.0 ml of Buffer A, transferred to clean plastic tubes, and assayed for radioactivity and protein. In some cases, hepatocytes were permeabilized with 0.055% (w/v) digitonin prior to addition of 125I-ASOR in order to measure the surface and intracellular pools of receptor activity on cells (15). To measure hepatocyte endocytosis of 125I-ASOR, cells in BME-BSA were incubated with 125I-ASOR at 37 °C for 45-60 min. Uptake was stopped rapidly by diluting the cells into a 5-10-fold excess volume of ice-cold Buffer A. To assay total cell-associated (surface and intracellular) 125I-ASOR, cells were washed by centrifugation twice in 2-4 ml of cold Buffer A. To assay internalized 125I-ASOR only, cells were washed by centrifugation twice, 5 min each wash, in 2-4 ml of Buffer B at 4 °C; EGTA present in Buffer B chelates Ca2+ required for ASOR binding to ASGP receptors, thereby dissociating cell surface receptor-ligand complexes. After washing, cells were resuspended in 0.5-1.0 ml of Buffer A, transferred to clean plastic tubes, and assayed for radioactivity and protein. In some experiments, we determined the extent of 125I-ligand degradation by cells by measuring the amount of acid-soluble radioactivity released into conditioned medium at 37 °C, as reported previously (16). Briefly, conditioned medium from cells incubated with 125I-ASOR were collected and clarified by centrifugation (400 × g, 2 min, 4 °C). 125I-Polypeptides in the conditioned media were precipitated by the addition of two volumes of cold 10% (w/v) phosphotungstic acid in 2 N HCl. After incubation for 15 min on ice, precipitated material was sedimented (4 °C, 4 min, 1000 × g); acid-precipitated pellets and acid-soluble supernatants were assayed for radioactivity.

Anti-RHL-1 Immunoglobulin Purification and Cell Surface RHL1 Protein Assay-- Anti-RHL1 sera were generated and analyzed as described elsewhere (6, 7). The whole Ig fraction from sera (immune and nonimmune) was isolated by chromatography on Protein A-agarose (Pierce) and iodinated with Na125I (14) to a final specific activity of 70-110 dpm/fmol. Hepatocytes in BME-BSA were incubated with or without CuCl2 (75 µM) or ZnCl2 (225 µM) for 2 h at 37 °C, then chilled on ice. The cells were washed free of metals by centrifugation in cold excess BME, then incubated with 125I-anti-RHL1 Ig or 125I-Ig (nonimmune) for 90 min at 4 °C with or without a 100-fold molar excess of unlabeled anti-RHL1 Ig or nonimmune Ig. The cells were collected by centrifugation, washed twice with excess cold Buffer A, then assayed for cell-associated radioactivity.

Pinocytosis Assay-- Control, CuCl2-treated, and ZnCl2-treated hepatocytes were incubated in the presence or absence of metals with BME-BSA supplemented with 0.2 mg/ml Lucifer Yellow for up to 1 h at 37 °C. Cells were chilled on ice, washed twice with excess cold BME-BSA, 10 min/wash, then solubilized at 4 °C for 20 min in 0.05% Triton X-100 containing 0.1% (w/v) BSA. Insoluble debris was sedimented by centrifugation (13,000 × g, 15 min, 4 °C), and supernatants were assayed for Lucifer Yellow fluorescence (excitation at 430 nm, emission at 540 nm) using a Fluoromax-2 spectrofluorimeter (Jobin Yvon Spex, Instruments S.A., Inc., Edison, NJ).

125I-Transferrin Binding and Endocytosis Assay-- Adult rat hepatocytes were plated on unmodified tissue culture plates and incubated overnight as described above. Prior to experiments, cells were incubated in BME-BSA (no serum present) with or without CuCl2 or ZnCl2 for 2 h at 37 °C. To determine surface binding of 125I-transferrin by hepatocytes, cells were chilled on ice and incubated 2 h with 125I-transferrin (2 µg/ml) in BME at 4 °C. The radioactive mixture was removed, and the cells were rinsed four times with cold Buffer A. The cell-bound radioactivity was solubilized by incubating the cells in 2 ml of Buffer A containing 2% (v/v) Triton X-100 at 37 °C for 2 h. Detergent-released 125I-radioactivity was transferred to clean tubes and assayed by gamma  spectroscopy. To determine 125I-transferrin endocytosis by hepatocytes, cells in BME-BSA were supplemented with 125I-transferrin (2 µg/ml) and incubated at 37 °C for 60 min, after which the cells were chilled on ice. Radioactive media were removed, and the cells were assayed for total bound 125I-transferrin as described above. To determine the amount of internal 125I-transferrin, rinsed cells at 4 °C were stripped of surface-bound 125I-transferrin by a 30-s exposure to 0.25 M acetic acid, 0.5 M NaCl, after which an equal volume of ice-cold 0.5 M Na2HPO4 was added to bring the pH to 7.5. Acid-released radioactivity was aspirated off the cells, and the cells were rinsed an additional three times with cold Buffer A. Acid-resistant radioactivity, deemed intracellular, was assayed following Triton X-100 solubilization as described above.

General Procedures-- Protein was determined by the bicinchoninic acid protein assay procedure using BSA as standard (Pierce). Centrifugation of cell suspensions was at 400 × g for 2 min at 4 °C using a Beckman GS-6R centrifuge equipped with a GH-3.8 rotor (Beckman Instruments, Inc., Fullerton, CA). 125I radioactivity was determined using a Packard Cobra Auto-Gamma counting system (model 5002; Packard Instrument Co., Downers Grove, IL). Spectroscopic measurements were done using a Shimadzu UV-160 spectrophotometer (Kyoto, Japan).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Zinc and Copper Block Sustained ASGP Receptor-dependent Endocytosis-- In the first series of experiments, we examined the effects of MnCl2, ZnCl2, or CuCl2 on sustained endocytosis (binding and internalization) of 125I-ASOR by hepatocytes. Cells exposed to MnCl2 (0-220 µM) exhibited no alteration in sustained endocytosis of 125I-ASOR (data not shown). In contrast, continuous internalization of 125I-ASOR by cells incubated with 0-220 µM ZnCl2 (Fig. 1A) or 0-225 µM CuCl2 (Fig. 1B) diminished up to at least 94%. Half-maximal inhibition of endocytosis (Fig. 1B, inset) was observed at 39 µM CuCl2 and 53 µM ZnCl2 although significant inhibition exerted by ZnCl2 occurred only at concentrations >20 µM. Inhibition of continuous 125I-ASOR endocytosis by ZnCl2 (220 µM) or CuCl2 (75 µM) was time-dependent (Fig. 2). The first-order half-time rates for loss of 125I-ASOR internalization were 62 min for zinc ions and 54 min for copper ions (Fig. 2, A and B, insets). Overall, the loss of 125I-ASOR binding and uptake followed similar dose-response curves (Fig. 1) and kinetics (Fig. 2). Regardless of the treatment, cell viability was not altered, as determined by trypan blue exclusion by control and metal-treated cells (data not shown). We also found that the effects of copper and zinc ions on continuous uptake of 125I-ASOR were additive (Fig. 3). Binding and internalization of 125I-ASOR were more greatly inhibited when cells were treated with a combination of ZnCl2 (220 µM) and CuCl2 (75 µM) (91% and 95% for zinc and copper, respectively) than when treated with either metal alone. We also found that the effects of zinc and copper ions on ASOR endocytosis were not ameliorated by co-incubation with the general reductant ascorbate (Table I). Notably, ascorbate (0.1 mM) enhanced the copper-dependent inhibition of ASOR binding and internalization compared with cells treated with copper ions alone.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Continuous endocytosis as a function of metal concentration. Hepatocytes (2 × 106 cells/ml) were incubated in BME-BSA with and without the designated concentrations of ZnCl2 (A) or CuCl2 (B) at 37 °C for 2 h. The cells were supplemented with 125I-ASOR (2 µg/ml), and the incubations were continued at 37 °C for an additional 60 min. The cells were chilled at 4 °C and assayed for total () and internalized (black-square) 125I-ASOR. Symbols reflect the mean of duplicate samples; error bars reflect the standard deviations of the means. Results shown in panels A and B were from experiments done on different days using different hepatocyte and 125I-ASOR preparations. The extent of inhibition (inset) was calculated according to the equation (Xmax - XC)/(Xmax - Xmin), where Xmax = maximal inhibition, XC = inhibition at metal concentration C, and Xmin = levels of 125I-ASOR total bound or internalized in the absence of added metal ions. Symbols represent extent of inhibition of 125I-ASOR binding (surface and intracellular; open circle , ) and internalization (, black-square) in the presence of copper (, black-square) or zinc (open circle , ) ions.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Kinetics of endocytosis inhibition. Hepatocytes (2 × 106 cells/ml) were incubated in BME-BSA with and without 225 µM ZnCl2 (A) or 75 µM CuCl2 (B) for the indicated times at 37 °C. The cells were supplemented with 125I-ASOR (2 µg/ml), and the incubation was continued for an additional 60 min at 37 °C. The cells were chilled at 4 °C and assayed for total bound () and internalized (black-square) 125I-ASOR. Symbols reflect the mean of duplicate samples; error bars reflect the standard deviations of the means. The metal-dependent inhibition of total binding and internalization of 125I-ASOR compared with nontreated control cells (% Control) was also plotted (insets). The inhibition of 125I-ASOR internalization followed first-order kinetics for both ZnCl2 (t1/2 = 62 min; r = -0.98, n = 6) and CuCl2 (t1/2 = 54 min; r = -0.97, n = 6).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of zinc and copper co-treatment on ASOR endocytosis. Hepatocytes (2 × 106 cells/ml) were incubated with BME-BSA with and without the indicated concentrations of ZnCl2 or CuCl2 at 37 °C for 2 h. The incubations were supplemented with 125I-ASOR (2 µg/ml) and the incubations continued at 37 °C for an additional 60 min. The cells were chilled at 4 °C, washed, and assayed for total and internalized 125I-ASOR. Values reflect the means of triplicate samples; error bars reflect the standard deviation of the means.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of ascorbate, Zn2+, and Cu2+ treatment on ASGP receptor endocytic activity
Hepatocytes (2 × 106 cells/ml) in BME-BSA were incubated with or without the designated amounts of ZnCl2, CuCl2, or ascorbate for 2 h at 37 °C. Cells were chilled at 4 °C, washed twice in BME-BSA to remove excess metal, then prebound with 125I-ASOR at 4 °C for 1 h. After cells were washed free of unbound 125I-ASOR, cells were resuspended in fresh BME-BSA with or without ZnCl2, CuCl2, or ascorbate (similar to that during the original 2-h incubation) and incubated at 37 °C for 15 min. The cells were chilled at 4 °C and assayed for total bound and internalized 125I-ASOR. Values represent the mean ± standard deviation of duplicate samples. Values as a function of a percentage of untreated control cells are included in parentheses.

The inhibition of ASGP receptor-dependent endocytosis by metal treatment was reversible. Cells treated with ZnCl2 or CuCl2 exhibited >60% loss in total (surface and intracellular) bound (Fig. 4A) and internalized (Fig. 4B) 125I-ASOR. When cells were washed free of metals and incubated in the absence of exogenous zinc and copper ions, they recovered their ability to bind and take up 125I-ASOR. These results indicate that the metal-sensitive sites required for endocytosis were either not irreversibly blocked by metal treatment or were readily replaced following de novo synthesis. In either case, these data support the conclusion that the block in endocytosis was not due to a loss of cell viability.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 4.   Reversibility of metal inhibition of ASOR endocytosis. Hepatocytes (4 × 106 cells/ml) in BME-BSA were treated with or without ZnCl2 (220 µM) or CuCl2 (75 µM) for 2 h at 37 °C. A portion of these cells were supplemented with 125I-ASOR (2 µg/ml) and incubated at 37 °C for 30 min, after which they were assayed for total bound (A) and internalized (B) 125I-ASOR (2 h ± metal). The remainder of the cells was chilled at 4 °C, washed twice in BME to remove excess metal, then resuspended into fresh BME-BSA and incubated 1 or 2 h at 37 °C. At each of these recovery times, some cells were supplemented with 125I-ASOR (2 µg/ml) and incubated an additional 60 min at 37 °C, after which they were assayed for total bound (A) and internalized (B) 125I-ASOR. Values represent the mean of duplicate samples; error bars reflect the standard deviations of the means. , no additions; , 220 µM ZnCl2; , 75 µM CuCl2.

In each of the preceding experiments, zinc- or copper-treated hepatocytes were examined for their ability to take up 125I-ASOR continuously during a 1-h assay period following a 2-h metal treatment period. As a result, inhibition of continuous endocytosis could reflect a block in one or more events including internalization of receptor-ligand complexes at the cell surface, intracellular processing of receptor-ligand complexes, or recycling of ASGP receptors. To determine if zinc or copper ions blocked internalization of receptor-ligand complexes at the cell surface, we examined the ability of metal-treated hepatocytes to internalize 125I-ASOR prebound on the cell surface (Fig. 5). We found that the amount of 125I-ASOR bound to the cells following zinc and copper treatment was reduced by 56% and 35%, respectively, reflecting a loss in the number of active ASGP receptors on the surfaces of metal-treated cells. Zinc-treated cells internalized progressively less 125I-ASOR as a function of ZnCl2 concentration but the percentage of bound 125I-ASOR that was internalized remained the same (~30%) regardless of the ZnCl2 concentration (Fig. 5A). In contrast, the percentage of prebound 125I-ASOR internalized by cells was reduced from 33% on control cells to <8% on cells treated with 75 µM CuCl2 (Fig. 5B). These results indicate that, although both metals reduced the number of active surface ASGP receptors, copper ions, but not zinc ions, blocked the ability of cells to internalize receptor-ligand complexes at the cell surface. These data also suggest that at least some of the sites sensitive to these two metals are different.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of zinc and copper on internalization of receptor-ligand complexes. Hepatocytes (2 × 106 cells/ml) in BME-BSA were incubated with and without 0-225 µM ZnCl2 (A) or 0-75 µM CuCl2 (B) for 2 h at 37 °C. Cells were chilled at 4 °C, washed once in BME to remove excess metal, then incubated with 125I-ASOR at 4 °C for 1 h to bind surface ASGP receptors. After they were washed free of unbound 125I-ASOR, cells were resuspended in fresh BME-BSA containing ZnCl2 or CuCl2 (at concentrations identical to those during the original 2-h incubation) and incubated at 37 °C for 10 min. The cells were chilled at 4 °C and assayed for total bound () and internalized (black-square) 125I-ASOR. Symbols represent the mean of duplicate samples; error bars reflect the standard deviations of the means. The percentage of total bound 125I-ASOR internalized by the cells (open circle ) equaled (125I-ASOR internal) div  (125I-ASOR total)×100.

Zinc and Copper Reduce Hepatocyte Surface ASGP Receptor Activity-- The previous experiments (Fig. 5, Table I) showed that copper- and zinc-treated hepatocytes reduced the number of active ASGP receptors on their surfaces. To address this issue more directly, we examined the ligand binding activity of surface and intracellular populations of ASGP receptors on metal-treated hepatocytes. Surface ASGP receptor activity was assayed on intact cells, whereas both surface and intracellular ASGP receptor activity was assayed on digitonin-permeabilized hepatocytes (15, 17). Treatment of cells with ZnCl2 or CuCl2 reduced surface binding of 125I-ASOR by up to 44% (Fig. 6A) and 48% (Fig. 6B), respectively. Permeable metal-treated cells also bound progressively less 125I-ASOR than did nontreated control cells. Notably, the absolute molar reduction of 125I-ASOR binding to permeable cells was similar to that observed for intact cells, such that the calculated number of active intracellular ASGP receptors was not altered by metal treatment (Fig. 6, A and B, closed circles). Thus, both copper and zinc ions induced a loss of surface ASGP receptor activity with no net change in the amount of intracellular receptor activity.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of zinc and copper on ASGP receptor ligand binding activity. A and B, hepatocytes (2 × 106 cells/ml) in BME-BSA were incubated with or without the designated concentrations of ZnCl2 (A) or CuCl2 (B) at 37 °C for 2 h. Cells were chilled on ice. Half of the cells were permeabilized with 0.06% (w/v) digitonin for 10 min at 4 °C, after which they were pelleted by centrifugation; supernatants were discarded. Intact () and permeable (black-square) cells were assayed for binding of 125I-ASOR at 4 °C. Symbols represent the means of duplicate samples; error bars reflect the standard deviations of the means. 125I-ASOR bound to intracellular ASGP receptors (; Internal) was calculated as the difference of 125I-ASOR bound to permeable v. intact cells. C and D, hepatocytes were incubated with or without 75 µM CuCl2 or 225 µM ZnCl2 for 2 h at 37 °C, after which the cells were chilled on ice. The cells were then assayed for 125I-ASOR binding at 4 °C (C) or for 125I-anti-RHL1 IgG binding at 4 °C (Total Binding; D). To determine nonspecific 125I-anti-RHL1 IgG binding to hepatocytes, incubations containing 125I-anti-RHL1 Ig were done in the presence of a 100-fold excess of unlabeled anti-RHL1 Ig; specific binding was calculated as the difference between total binding and nonspecific binding. Values represent the means of duplicate samples; error bars reflect the standard deviations of the means.

The loss of receptor-ligand binding activity observed in the previous experiment does not necessarily reflect the loss of receptor protein from the cell surface. Thus, we examined the surfaces of metal-treated cells for the presence of immunodetectable ASGP receptor protein by assaying their ability to bind 125I-anti-RHL1 Ig. As expected, CuCl2 (75 µM) and ZnCl2 (225 µM) reduced 125I-ASOR bound to cells by 40% and 70%, respectively (Fig. 6C). Accordingly, zinc-treated cells bound ~50% less 125I-anti-RHL1 Ig than did control cells indicating that RHL1 protein was lost from the cell surface. In contrast, copper-treated cells exhibited no loss of 125I-anti-RHL1 Ig binding (Fig. 6D). Treatment of cells with zinc or copper ions at 4 °C either before or during the 125I-anti-RHL1 Ig binding assay did not alter 125I-anti-RHL1 Ig binding to the cells,2 indicating that copper and zinc ions per se did not interfere with antibody binding to the receptor. Taken together, these data indicate that copper-treated cells accumulated inactive ASGP receptors at the cell surface with no significant change in the distribution of RHL1 subunits between the cell surface and cell interior. Because zinc ion-treated cells lost surface ASGP receptor activity and protein without an increase in intracellular ASGP receptor activity (Fig. 6A), we conclude that zinc-treated cells accumulated inactive ASGP receptors intracellularly.

In other experiments, we found that the metal-induced reduction of surface ASGP receptor activity was temperature-dependent. Cells treated with various concentrations of zinc or copper ions at 4 °C showed no loss of surface binding of 125I-ASOR (Fig. 7A) compared with cells pretreated at 37 °C with either CuCl2 or ZnCl2 alone or in combination (Fig. 7B). These data indicated that metal-induced losses of surface receptor activity results from perturbations in one or more cellular processes rather than direct interference of metals on the ability of ASGP receptors to bind ligand per se. Notably, significant metal-dependent reductions of surface 125I-ASOR binding were evident only when cells were exposed to metal ions at or above 22 °C (Fig. 7C), and 125I-ASOR binding was actually higher on samples treated with different levels of CuCl2 than on control cells. In other experiments, we found that the ASGP receptor binding of ASOR was partially reduced for zinc-treated 125I-ASOR (Table II). When cells were incubated with 125I-ASOR and zinc or copper ions simultaneously at 4 °C, binding of 125I-ASOR was the same as control cells. If, however, 125I-ASOR was mixed with ZnCl2 at 22 °C for 1 h prior to addition to untreated hepatocytes at 4 °C, cells bound 28% less 125I-ASOR compared with non-pretreated 125I-ASOR (Table II). In contrast, 125I-ASOR pretreated with 75 µM CuCl2 maintained >90% of its cell binding activity. The inhibitory effects of zinc ions on 125I-ASOR were reversed if zinc-treated 125I-ASOR was dialyzed free of zinc ions prior to addition to hepatocytes. These data suggest that zinc ions bind reversibly to ASOR, possibly in a temperature-dependent manner, and reduce at least partially its ability to bind ASGP receptors.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of temperature on metal-induced loss of surface ASGP receptor activity. A, hepatocytes (2 × 106 cells/ml) in BME-BSA were incubated with and without ZnCl2 or CuCl2 at the indicated concentrations for 2 h at 4 °C. Cells were washed once in BME, then assayed for 125I-ASOR binding at 4 °C. Symbols represent means of duplicate samples; error bars reflect standard deviations of the means. B, hepatocytes (2 × 106 cells/ml) in BME-BSA were incubated for 2 h with or without 225 µM ZnCl2 or 75 µM CuCl2 at either 4 °C or 37 °C. Cells were chilled at 4 °C, washed twice in HBS to remove excess metal, then assayed for bound 125I-ASOR. Symbols represent means of duplicate samples; error bars reflect standard deviations of the means. C, hepatocytes (2 × 106 cells/ml) in BME-BSA were incubated for 2 h with or without 225 µM of ZnCl2 or 75 µM of CuCl2 at the indicated temperatures. The cells were chilled, washed twice to remove excess metal, then assayed for 125I-ASOR binding at 4 °C. Symbols represent means of duplicate samples; error bars reflect standard deviations of the means.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of Zn2+ and Cu2+ on ASGP receptor ligand-binding activity
In experiment 1, hepatocytes (2 × 106) were incubated with 125I-ASOR in the presence or absence of 220 µM ZnCl2 or 75 µM CuCl2 for 1 h at 4 °C, after which the cells were assayed for bound radioactivity. In experiment 2, 125I-ASOR was preincubated with or without 220 µM ZnCl2 or 75 µM CuCl2 for 1 h at 22 °C, dialyzed overnight against HBS to remove metals, then assayed for binding on hepatocytes (4 × 106 cells/ml) at 4 °C for 1 h. Values represent the means of duplicate samples ± standard deviation.

Effect of Zinc and Copper on Intracellular Processing of ASGP Receptors and ASOR Degradation-- About half of the ASGP receptors on isolated rat hepatocytes recycle constitutively, whereas the rest recycle only during endocytosis (18). Reduced surface ASGP receptor activity and ASGP receptor-dependent endocytosis on metal-treated hepatocytes may reflect, in part, an interruption in the return of recycling ASGP receptors back to the cell surface. If metal treatment interferes with ASGP receptor recycling, then one would predict that the loss of surface ASGP receptor activity would be more pronounced if hepatocytes were actively endocytosing ASOR during treatment with copper or zinc ions. To test for this, hepatocytes were treated with various concentrations of ZnCl2 or CuCl2 in the presence or absence of excess ASOR, after which cells were stripped of surface-bound ASOR and assayed for surface ASGP receptor activity by 125I-ASOR binding at 4 °C (Fig. 8). Hepatocytes subjected to an endocytic load in the absence of metals possessed ~10% fewer active ASGP receptors than did cells not exposed to ASOR, presumably due to a minor ASOR-induced shift in the steady state distribution of ASGP receptors between the cell surface and cell interior. As anticipated, hepatocytes treated with either metal lost 50-60% of their surface ASOR binding activity. The ASOR-dependent reduction in surface ASGP receptor activity was not enhanced when cells were treated with zinc ions (Fig. 8A). On the other hand, cells treated with 75 µM CuCl2 showed a significant ASOR-dependent reduction in surface ASGP receptor activity (Fig. 8B), suggesting that copper ions, but not zinc ions, partially blocked the return of recycling ASGP receptors back to the cell surface. Cells treated with 225 µM CuCl2 (Fig. 8B) in the presence of added ASOR showed no loss of surface 125I-ASOR binding over and above that observed for cells treated with copper ions alone. This suggests the possibility that, at high copper ion concentrations, the ability of cells to internalize and recycle ASGP receptors is so severely impaired that ligand-stimulated receptor recycling is not observed.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of endocytic load during metal treatment on surface ASGP receptor activity. Hepatocytes (2 × 106 cells/ml) in BME-BSA were incubated with or without ZnCl2 (A) or CuCl2 (B) in the presence (black-square) or absence () of ASOR (2 µg/ml) at 37 °C for 2 h. The cells were chilled at 4 °C, washed in Buffer B at 4 °C to remove surface-bound ASOR, then assayed for 125I-ASOR binding at 4 °C. Symbols represent means of duplicate samples; error bars reflect standard deviations of the means.

We also examined the effects of zinc and copper ions on the lysosomal delivery and degradation of internalized 125I-ASOR. In this experiment, hepatocytes were prebound with 125I-ASOR at 4 °C, then incubated at 37 °C. At various times after the temperature shift, the cells were supplemented with metals and the 37 °C incubation was continued for up to 2 h at which time the amounts of cell-associated 125I-ASOR and 125I-degradation products released from the cells were determined (Fig. 9). We found that neither zinc (Fig. 9A) nor copper (Fig. 9B) ions significantly altered the amount of 125I-ASOR degraded by the cells as measured by the release of acid-soluble radioactivity from the cells, even if metals were added just 10 min following the shift to 37 °C. These results indicate that neither zinc nor copper ions perturbs the intracellular dissociation of internalized ASGP receptor-ASOR complexes or the delivery of ASOR to lysosomes and its subsequent degradation.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of metal treatment on degradation of internalized 125I-ASOR. Hepatocytes (2 × 106 cells/ml) in BME-BSA were incubated with 125I-ASOR at 4 °C for 1 h, after which they were washed twice in Buffer A to remove unbound 125I-ASOR. Cells were resuspended in fresh BME-BSA and incubated at 37 °C. At the indicated times, cells were supplemented with ZnCl2 (225 µM; A) or CuCl2 (75 µM; B), and the incubation was continued for a total of 2 h. Samples shown at 120 min were not exposed to added metals. The cells were chilled at 4 °C. Cell media were collected and assayed for acid-soluble (black-square) and acid-precipitable (open circle ) radioactivity. Cells were assayed for associated radioactivity (). Symbols represent the means of duplicate samples; error bars reflect the standard deviations of the means. Plotted lines are the best-fit curves calculated by linear regression (y = mx + b) of data points.

Effect of Copper and Zinc on Fluid-phase Pinocytosis and Transferrin Endocytosis-- The preceding results collectively show that zinc and copper ions strongly block ASGP receptor-mediated endocytosis. The question arises as to whether or not the inhibitory effects of these metal ions are specific for ASGP receptors or whether other vesicular uptake pathways are also sensitive to the effects of these metals. In the first series of experiments, we determined if fluid-phase uptake by hepatocytes was altered by copper or zinc ions. It has been shown that clathrin-dependent receptor-mediated endocytosis and pinocytosis can be uncoupled in hepatocytes by K+ depletion or by hyperosmotic treatment (19). In this experiment, isolated rat hepatocytes were treated at 37 °C for 2 h with or without ZnCl2 (225 µM) or CuCl2 (75 µM). After incubation, the cells were assayed for 125I-ASOR endocytosis, to measure ASGP receptor activity, and Lucifer Yellow uptake, to measure fluid-phase pinocytosis. As anticipated, zinc and copper ions inhibited 125I-ASOR total binding and uptake by up to 80% and 85%, respectively (Fig. 10A). Under these conditions, however, Lucifer Yellow uptake was largely unaffected (Fig. 10B). These findings suggest strongly that neither zinc nor copper ions interrupted clathrin-independent fluid phase vesicular transport in hepatocytes.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 10.   Effect of metal treatment on fluid-phase uptake. Hepatocytes (4 × 106 cells/ml) in BME-BSA were incubated in the absence () or presence of CuCl2 (black-square) or ZnCl2 (open circle ) for 2 h at 37 °C. Cell samples were supplemented with 125I-ASOR (2 µg/ml) and Lucifer Yellow (0.2 mg/ml) and incubated an additional 60 min. The cells were chilled on ice and washed twice with cold BME-BSA (10 min/wash). Cells were solubilized in HBS supplemented with 0.05% (v/v) Triton X-100 and BSA (1 mg/ml) for 30 min at 4 °C, after which insoluble debris was sedimented by centrifugation (13,000 × g, 4 °C, 15 min). Supernatants were assayed for 125I-ASOR (A) and Lucifer Yellow (B). Symbols represent the mean of duplicate samples; error bars reflect the standard deviations of means.

Finally, we examined the effect of copper or zinc loading on transferrin binding and endocytosis by hepatocytes. We found that copper-treated hepatocytes showed no alteration in 125I-transferrin binding at 4 °C or 125I-transferrin binding and internalization at 37 °C (Fig. 11B) in contrast to 125I-ASOR endocytosis, which was blocked by ~70% (Fig. 11A). Zinc treatment of hepatocytes, however, elicited a 50% reduction in surface 125I-transferrin binding at 4 °C and a 35% reduction in 125I-transferrin internalization at 37 °C (Fig. 11B). We found that preincubation of 125I-transferrin with ZnCl2 did not alter its ability to bind to hepatocytes subsequently.2 These data indicate, therefore, that zinc treatment of hepatocytes partially disrupted their ability to endocytose transferrin.


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 11.   Effect of metal treatment on hepatocyte binding and uptake of transferrin. Cultured adult hepatocytes in BME-BSA were incubated without or with ZnCl2 (225 µM) or CuCl2 (75 µM) for 2 h at 37 °C. Some cell samples were supplemented with either 125I-ASOR (2 µg/ml; A) or 125I-transferrin (2 µg/ml; B) and incubated at 37 °C for an additional 60 min, whereupon the cells were chilled on ice and assayed for bound and internalized 125I-ASOR and 125I-transferrin. Other cell samples were chilled on ice following metal treatment, washed, and assayed for surface binding of 125I-transferrin (B) at 4 °C. Values represent the means of duplicate samples; error bars reflect the standard deviations of the means.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Specificity of Copper and Zinc Inhibition of Endocytosis-- We are interested in understanding the role metalloproteins play in vesicular transport and the sensitivity of membrane dynamics toward metal toxicity. In this study, we have examined the effects of zinc and copper ion exposure on vesicular transport in isolated rat hepatocytes. Several lines of evidence support the view that the effects of copper and zinc were specific for receptor internalization and recycling and not for vesicular transport in general. First, neither metal blocked significantly the transport to and subsequent degradation of internalized ASOR in lysosomes (Fig. 9), even though both copper and zinc ions severely reduced continuous ASOR endocytosis (Figs. 1-3 and 11). These data suggest that copper and zinc ions under these conditions do not block ASGP receptor/ASOR dissociation and segregation for ASOR en route to lysosomes. Second, copper and zinc ions did not alter appreciably fluid-phase pinocytosis of Lucifer Yellow by hepatocytes under conditions where ASOR endocytosis was severely reduced (Fig. 10). Hepatocytes internalize bulk fluid predominately by a clathrin-independent pathway such that hyperosmotic disruption of clathrin-dependent uptake of ASOR by ASGP receptors has little or no effect on Lucifer Yellow uptake (19). Thus, the molecular machinery that mediates vesicular budding for this clathrin-independent pathway apparently is not susceptible to the effects of copper or zinc ions. Third, transferrin endocytosis in copper-treated hepatocytes was not reduced, as was ASOR endocytosis (Fig. 11). These data suggest that the effects of copper ions on ASGP receptor-dependent uptake were specific for this receptor and not inhibitory for endocytosis in general. In contrast, zinc ions blocked or reduced uptake of ASOR and transferrin by hepatocytes, suggesting the possibility that a mechanism or structural motif necessary for the proper functioning of these two receptors was sensitive to the effects of zinc ions.

Although the effects of copper and zinc ion exposure were relatively specific for ASGP receptor-mediated endocytosis, not all ASGP receptors responded to metal treatment equally. In several experiments, we found that only a portion of surface ASGP receptor activity was lost when cells were exposed to copper or zinc ions (Figs. 5-8). In one instance, metal-dependent reductions of surface 125I-ASOR binding were evident only when cells were exposed to metal ions at or above 22 °C (Fig. 7C), and cells treated with copper ions at temperatures below 33 °C frequently expressed more surface ASGP receptor activity than did control cells (Fig. 7C). Copper ion transport in rat cells is temperature-dependent (20), and the amount of copper or zinc ions accumulated by hepatocytes necessary to block endocytosis may be temperature-dependent. Alternatively, it may be that copper and zinc ions exert their effects only on ASGP receptors actively moving along the endocytic pathway. Only a subset of ASGP receptors, termed "state 2" ASGP receptors (21), recycle constitutively. When isolated rat hepatocytes are incubated at temperatures below 37 °C, the surface:intracellular ratio of state 2 ASPG receptors reversibly decreases (22). Accordingly, copper-treated hepatocytes may have consistently expressed higher surface ASGP receptor activity than did control cells (Fig. 7C) because copper ions, by inhibiting ASGP receptor internalization (Fig. 5), blocked the temperature-induced shift of receptors from the cell surface to the cell interior. Even so, it is expected both "state 1" and state 2 receptor classes are sensitive to these metals under conditions when both populations are mediating endocytosis of ligand.

Effect of Transition Metals on ASGP Receptor Activity-- Copper and zinc ions induced cells to accumulate a portion of their ASGP receptors in an inactive form (Fig. 6). Hepatocytes depleted of ATP or treated with agents that alkalinize acidic endosomal compartments (e.g. chloroquine, monensin) reversibly accumulate inactive ASGP receptors with no loss of total detectable ASGP receptor protein (22, 23). Weigel and colleagues (24-26) have found a direct correlation between ASGP receptor ligand binding activity and receptor palmitoylation (at Cys35 of RHL1) such that deacylated ASGP receptor subunits do not bind ASOR. In addition, constitutive recycling of ASGP receptors and receptor inactivation/reactivation are not necessarily coupled, as monensin treatment (22) and copper treatment (this report) induce the loss of ligand binding activity of ASGP receptors at the cell surface with little or no loss of immunodetectable receptor protein. Because copper treatment blocks ASGP receptor internalization (Figs. 5 and 8), it is likely that inactive ASGP receptors are accumulating on the surfaces of copper-treated cells. On the other hand, zinc-treated hepatocytes lost both ASGP receptor activity and immunodetectable RHL1 protein from the cell surface (Figs. 5 and 6), and this lost surface ASGP receptor activity was not recovered when permeable cells were assayed for 125I-ASOR binding (Fig. 6). It appears, therefore, that zinc-treated cells accumulated inactive ASGP receptors intracellularly, as zinc treatment alone did not block internalization of receptors from the cell surface (Fig. 5).

Our previous observations, which showed a correlation between iron-dependent inactivation of ASGP receptors and formation of disulfide-bonded RHL1 multimers, suggested the possibility that iron-dependent oxidation of Cys35 could preclude RHL1 acylation and thereby promote receptor inactivation (8, 9). We have found that hepatocytes treated with copper or zinc ions lose <= 90% of reduced glutathione content,2 suggesting that both metals induce a shift in the oxidative status of the cells. Under these conditions, we frequently (but not always) detect RHL1 dimers formed to a limited extent in hepatocytes treated with copper ions; we have never detected RHL1 multimers on zinc ion-treated cells.2 Thus, copper and zinc ions may induce ASGP receptor inactivation by disrupting receptor reacylation via a mechanism other than oxidation of Cys35.

Nature of Copper- and Zinc-sensitive Sites-- The nature of copper or zinc ion inhibition of ASGP receptor-mediated endocytosis is unclear. Both Cu2+ and Zn2+ are borderline metals and show increased binding strength to organic ligands compared with class A metals (e.g. K+, Na+, Mg2+, and Ca2+)(10). Zinc ions typically function by conferring specific structures to proteins they bind (e.g. zinc-finger proteins), whereas copper ions perform redox reactions in copper ion-bound proteins (e.g. superoxide dismutase). One possible mode of endocytic interruption is that OH· generated by copper ion-mediated Fenton reaction would oxidatively damage lipids and proteins crucial for normal uptake and recycling of ASGP receptors (1). Evidence arguing against this possibility includes the following. (i) The copper ion inhibition of ASOR binding and endocytosis were largely reversed following incubation of copper-treated cells in the absence of copper ions (Fig. 4). Protein and lipid damage mediated by reactive oxygen species is essentially irreversible with the exception of disulfide bond formation, which can be reversed by glutathionered-mediated reduction (27). Our results, however, do not rule out the possibility that some recovery was due to de novo synthesis of ASGP receptors. (ii) Copper ions did not alter significantly bulk-phase pinocytosis of Lucifer Yellow or transferrin endocytosis by treated hepatocytes. Because transferrin and ASOR are internalized by the same set of endocytic machinery, inactivation or damage exerted on this machinery by reactive oxygen species would block uptake of both ligands. (iii) We did not observe significant diminishment of cell viability as a result of copper ion treatment. (iv) Exposure of hepatocytes with up to 220 µM MnCl2 had no detectable effect on ASGP receptor-mediated endocytosis. This finding is significant because manganese ions have been shown to facilitate generation of reactive oxygen species (27). Because zinc ions are not redox active and do not mediate production of reactive oxygen species, these findings taken together suggest that reactive oxygen species were not responsible for the inhibitory effects of these metal ions on ASGP receptor-mediated endocytosis.

An alternate hypothesis is that copper and zinc ions bind ASGP receptors and interfere directly with their function. RHL1 does not contain canonical copper or zinc ion binding domains (e.g. MXM, MXXM, CC, CXC, or CXXC) present in metallothioneins (28) or FYVE-finger proteins (29). Even so, copper and zinc ions likely coordinate with a common set of histidyl and carboxyl groups on the RHL1 cytoplasmic domain, some of which are located near the internalization signal YQDF (amino acids 5-8) (30). Nonetheless, we observed significant differences in the effects of the two metals. First, unlike copper ions, zinc ions did not block internalization of receptor-ligand complexes from the cell surface (Fig. 5). Second, ASOR binding to ASGP receptors was itself partially altered by zinc ions but not by copper ions (Table II). Regardless, the extent of zinc-dependent inhibition of endocytosis and accumulation of inactive ASGP receptors cannot be attributed solely to the direct inhibition of ASOR binding by zinc ions (<30% reduction, Table II). Third, zinc ions, but not copper ions blocked at least partially transferrin endocytosis (Fig. 11). Fourth, inhibition of ASOR endocytosis required higher zinc ion concentrations compared with copper ions (Figs. 1, 5). Thus, copper and zinc ions may bind to elements of the cytoplasmic tail of ASGP receptor subunits which directly or indirectly interferes with the internalization signal (copper ions) or the trafficking of ASGP receptors (and transferrin receptors in the case of zinc ions) back to the cell surface, thereby, diminishing sustained endocytosis.

Our findings here provide evidence that transition metal toxicity on cells can be highly specific toward the function of membrane proteins. We are currently investigating whether or not iron, copper, and zinc interact with the cytoplasmic tail of RHL1 subunits, and if so, determine the specific amino acids involved in that interaction.

    ACKNOWLEDGEMENTS

We thank Dr. Jeff Cohlberg for the use of his spectrofluorimeter, and we thank Dr. Jeff Cohlberg, Dr. Zed Mason, and Dr. Editte Gharakhanian for helpful discussions during the preparation of the manuscript.

    FOOTNOTES

* This work was supported by Grant DK 43355 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Chemistry and Biochemistry, California State University, 1250 Bellflower Blvd., Long Beach, CA 90840. Tel.: 562-985-1558; Fax: 562-985-8557; E-mail: dmcabee{at}csulb.edu.

2 D. D. McAbee and X. Jiang, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: RHL, rat hepatic lectin; ASGP, asialoglycoprotein; ASOR, asialoorosomucoid; BME, basal medium Eagle's; BSA, bovine serum albumin; HBS, HEPES-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Berlett, B. S., and Stadtman, E. R. (1997) J. Biol. Chem. 272, 20313-20316[Free Full Text]
  2. Henle, E. S., and Linn, S. (1997) J. Biol. Chem. 272, 19095-19098[Free Full Text]
  3. De Silva, D. M., Askwith, C. C., and Kaplan, J. (1996) Physiol. Rev. 76, 31-47[Abstract/Free Full Text]
  4. Linder, M. C., and Hazegh-Azam, M. (1996) Am. J. Clin. Nutr. 63, 797S-811S[Abstract]
  5. Eide, D. (1997) Curr. Opin. Cell Biol. 9, 573-577[CrossRef][Medline] [Order article via Infotrieve]
  6. Bennatt, D. J., and McAbee, D. D. (1997) Biochemistry 36, 8359-8366[CrossRef][Medline] [Order article via Infotrieve]
  7. Bennatt, D. J., Ling, Y. Y., and McAbee, D. D. (1997) Biochemistry 36, 8367-8376[CrossRef][Medline] [Order article via Infotrieve]
  8. McAbee, D. D., and Ling, Y. Y. (1997) J. Cell. Physiol. 171, 75-86[CrossRef][Medline] [Order article via Infotrieve]
  9. McAbee, D. D., Ling, Y. Y., and Stich, C. (1998) Biochem. J. 331, 719-726[Medline] [Order article via Infotrieve]
  10. Mason, A. Z., and Jenkins, K. D. (1995) in Metal Speciation and Bioavailability (Tessier, A., and Turner, D. R., eds), pp. 479-608, John Wiley & Sons, New York
  11. Seglen, P. O. (1973) Exp. Cell Res. 82, 391-398[Medline] [Order article via Infotrieve]
  12. McAbee, D. D., and Esbensen, K. (1991) J. Biol. Chem. 266, 23624-23631[Abstract/Free Full Text]
  13. Schachter, H., Jabbal, I., Hudgin, R. L., Pinteric, L., McGuire, E. J., and Roseman, S. (1970) J. Biol. Chem. 245, 1090-1100[Abstract/Free Full Text]
  14. Fraker, P. J., and Speck, J. C. (1978) Biochem. Biophys. Res. Commun. 80, 849-857[Medline] [Order article via Infotrieve]
  15. Weigel, P. H., Ray, D. A., and Oka, J. A. (1983) Anal. Biochem. 133, 437-449[Medline] [Order article via Infotrieve]
  16. McAbee, D. D., Nowatzke, W., Oehler, C., Sitaram, M., Sbaschnig, E., Opferman, J. T., Carr, J., and Esbensen, K. (1993) Biochemistry 32, 13749-13760[Medline] [Order article via Infotrieve]
  17. McAbee, D. D., and Weigel, P. H. (1987) J. Biol. Chem. 262, 1942-1945[Abstract/Free Full Text]
  18. Weigel, P. H. (1993) Subcell. Biochem. 19, 125-161[Medline] [Order article via Infotrieve]
  19. Oka, J. A., Christensen, M. D., and Weigel, P. H. (1989) J. Biol. Chem. 264, 12016-12024[Abstract/Free Full Text]
  20. Qian, Y., Tiffany-Castiglioni, E., and Harris, E. D. (1995) Am. J. Physiol. 269, C892-C898[Abstract/Free Full Text]
  21. Weigel, P. H., and Oka, J. A. (1998) Biochem. Biophys. Res. Commun. 246, 563-569[CrossRef][Medline] [Order article via Infotrieve]
  22. McAbee, D. D., Lear, M. C., and Weigel, P. H. (1991) J. Cell. Biochem. 45, 59-68[Medline] [Order article via Infotrieve]
  23. McAbee, D. D., and Weigel, P. H. (1988) Biochemistry 27, 2061-2069[Medline] [Order article via Infotrieve]
  24. Weigel, P. H., Medh, J. D., and Oka, J. A. (1994) Mol. Biol. Cell 5, 227-235[Abstract]
  25. Zeng, F. Y., Kaphalia, B. S., Ansari, G. A. S., and Weigel, P. H. (1995) J. Biol. Chem. 270, 21382-21387[Abstract/Free Full Text]
  26. Zeng, F.-Y., and Weigel, P. H. (1996) J. Biol. Chem. 271, 32454-32460[Abstract/Free Full Text]
  27. Stadtman, E. R. (1993) Annu. Rev. Biochem. 62, 797-821[CrossRef][Medline] [Order article via Infotrieve]
  28. Palmiter, R. D. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8428-8430[Abstract/Free Full Text]
  29. Stenmark, H., Aasland, R., Toh, B. H., and D'Arrigo, A. (1996) J. Biol. Chem. 271, 24048-24054[Abstract/Free Full Text]
  30. Trowbridge, I. S., and Callawn, J. F. (1992) J. Inorg. Biochem. 47, 209-217[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.